SEC Form 4 · accession 0001650664-26-000056
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilmore Neil O'Neill
Officer — CEO · Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:33 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 3, 2026 | S | 15,380 | $2.7011 | D | 248,313 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
- F2This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.